Description: Poolbeg Pharma PLC operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. Its products include POLB 001, a Phase-II ready p38 MAP Kinase inhibitor that reduces harmful inflammation in patients with severe forms of influenza; PredictViral Biomarker Platform, a tool for predicting severe diseases; and vaccine discovery platform, which are techniques used in human challenge models to identify vaccine candidates that drive preferential T-Cell immune responses. The company was formerly known as Orph Pharma Limited and changed its name to Poolbeg Pharma PLC in June 2021. Poolbeg Pharma PLC was incorporated in 2021 and is headquartered in London, the United Kingdom.
Home Page: www.poolbegpharma.com
POLB Technical Analysis
Queen Mary BioEnterprises Innovation Ctr
London,
E1 2AX
United Kingdom
Phone:
44 20 7183 1499
Officers
| Name | Title |
|---|---|
| Dr. Jeremy Skillington Ph.D. | CEO & Director |
| Mr. Ian O'Connell | CFO & Director |
| Mr. Salim Hamir F.C.A. | Company Sec. |
| Mr. Ross Crockett | Group Financial Controller |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |